Monday, January 10, 2022 4:38:18 PM
NWBO has NO manufacturing facilities in the US. They will NEVER have any manufacturing facilities in the US. They will sign an agreement with a company when time comes to produce their vaccines.
I am assuming that what you are set on means they are funding CRL's expansion is this sentence: "Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe."
I am astounded that this in your mind means that we are funding CRL's expansion. It could be referring to the development, implementation and approval of Flaskworks, which can be done in corporation with any University or research facility. In addition, it could refer to payments to UCLA or other research facilities to get new trials going.
As they do not have any agreement with CRL at this time, funding their build out is likely the least reasonable option
I am assuming that what you are set on means they are funding CRL's expansion is this sentence: "Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe."
I am astounded that this in your mind means that we are funding CRL's expansion. It could be referring to the development, implementation and approval of Flaskworks, which can be done in corporation with any University or research facility. In addition, it could refer to payments to UCLA or other research facilities to get new trials going.
As they do not have any agreement with CRL at this time, funding their build out is likely the least reasonable option
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
